Immunic Inc. | VTL

Stock Price
1.58
Daily Change
-2.47%
Yearly
-53.39%
Q2 Forecast
1.66
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
BioMarin Pharmaceutical 93.25 4.99 5.65% 20.34%
Dynavax Technologies 11.58 0.10 0.87% -4.46%
Enanta Pharmaceuticals 25.76 1.01 4.08% -40.54%
Intercept Pharmaceuticals 11.02 0.29 2.70% -32.72%
Insmed 19.48 0.24 1.25% -0.26%
Mirati Therapeutics 38.14 1.13 3.05% -13.96%
Omeros 7.40 0.12 1.65% 196.00%
OraSure Technologies 5.72 0.19 3.35% 48.44%
Quidel 86.11 0.46 0.54% -4.26%
Ultragenyx Pharmaceutical 50.59 0.98 1.97% -1.60%
Regulus Therapeutics 1.33 0 0% 387.18%
Revance Therapeutics 31.01 0.60 1.97% 133.16%
United Therapeutics 215.53 2.05 0.96% -5.73%
Immunic Inc. 1.58 -0.04 -2.47% -53.39%
Xoma 18.08 1.07 6.29% -1.69%

Indexes Price Day Year
USND 13247 142.90 1.09% 10.27%
US2000 1829 60.83 3.44% -2.84%

Immunic Inc.

Immunic Inc. traded at $1.57 this Friday June 2nd, decreasing $0.06 or 3.40 percent since the previous trading session. Looking back, over the last four weeks, Immunic Inc. lost 9.54 percent. Over the last 12 months, its price fell by 53.83 percent. Looking ahead, we forecast Immunic Inc. to be priced at 1.66 by the end of this quarter and at 1.52 in one year, according to Trading Economics global macro models projections and analysts expectations.

Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.